Overview

Paranasal sinus and nasal cavity plasmacytoma is a relatively uncommon cancer arising from plasma cells, specialized white blood cells that produce antibodies. It is categorized as a plasma cell neoplasm and can be either a solitary plasmacytoma limited to the sinonasal area or part of multiple myeloma. Early diagnosis is important in assessing the extent of disease and in guiding appropriate management.

At Tender Palm Hospital, Gomti Nagar, Lucknow, our Head & Neck Oncology experts provide a full spectrum of diagnostic, staging, treatment, and follow-up care services for patients with plasmacytomas affecting the nasal cavity and paranasal sinuses.

What is Plasmacytoma?

Plasmacytoma is an uncontrolled proliferation of plasma cells in a particular site. An extramedullary plasmacytoma (EMP) occurs when there is the formation of a tumor made up of plasma cells anywhere other than the bone marrow, including the nasal cavity and paranasal sinuses.

Unlike other sinonasal malignancies, which arise from lining cells of the nose and sinuses, plasmacytoma develops from plasma cells within the immune system. Even though local in many cases when diagnosed, the condition must be thoroughly evaluated because there is a possibility of association with or progression to multiple myeloma.

Is Plasmacytoma One of the Paranasal Sinus & Nasal Cavity Cancers?

Yes. Plasmacytoma is one of the malignant neoplasms of the nasal cavity and paranasal sinuses. Nevertheless, it is uncommon. It is a type of hematologic cancer, unlike epithelial cancers such as squamous cell carcinoma and adenocarcinoma.

Since the treatment and prognosis differ for plasmacytoma from other sinonasal malignancies, accurate diagnosis is important.

What Are Paranasal Sinuses and Nasal Cavity?

The nasal cavity is the nasal airway that cleans, warms, and moistens inhaled air.

The paranasal sinuses are a collection/group of air spaces that surround the nasal cavity and consist of and they consist of:

• Maxillary sinuses
• Ethmoid sinuses
• Frontal sinuses
• Sphenoid sinuses

Extramedullary plasmacytomas often affect the nasal cavity, nasopharynx, and upper respiratory tract, but they can also involve the paranasal sinuses.

How Prevalent is Plasmacytoma?

Plasmacytoma is quite rare, representing less than 1% of all head and neck cancers.

Estimates suggest that 80-90% of extramedullary plasmacytomas arise in the head and neck region, and the sinonasal tract is one of the most common extra-bone marrow locations.

It is more common among males and is usually seen among adults aged 50 to 70 years.

What Triggers Plasmacytoma?

The trigger is currently unknown.

Experts say the disorder results from genetic alterations that lead to abnormal growth of plasma cells.

Some of the factors that might be involved in the development of the disease include:

• Advancing age
• Long-term immune stimulation
• Some genetic abnormalities
• History of radiation therapy (rare)
• Hereditary disorders related to plasma cells (uncommon)

Contrary to many other sinonasal tumors, plasmacytoma is not associated with tobacco smoking or dust exposure in the workplace.

What are the Risk Factors

At-risk groups include:

• Adults above 50 years
• Males
• Persons with plasma cell disorders
• People with immune system abnormalities
• Patients affected with monoclonal gammopathy of unknown significance (MGUS)

However, some patients have no known risk factors.

What Are the Signs of Plasmacytoma?

They usually develop gradually and mimic the symptoms of chronic sinusitis.

Typical signs include:

• Chronic nasal obstruction
• Repeated nosebleeds
• Nasal swelling or lump
• Bloodstained nasal discharge
• Headaches
• Altered sense of smell
• Swollen facial features
• Swelling of the eye or double vision if other structures are affected
• Recurring sinus infections that remain unresponsive to treatment.

The signs are dependent on the size and location of the plasmacytoma.

When Should You Visit a Physician?

You should visit an ENT specialist if you have:

• Chronic unilateral nasal obstruction
• Repeated nosebleeds
• Swelling or a growth in the nose
• Swelling or pain in the face
• Unresolved sinus problems despite treatment
• Difficulties with vision
• Unexpected nasal bleeding

Early diagnosis helps with treatment planning and the exclusion of multiple myeloma.

How Is Plasmacytoma Diagnosed?

Plasmacytoma diagnosis involves conducting a number of tests to establish the presence of the tumor and whether it is localized or systemic.

Medical History and Clinical Examination

A comprehensive clinical and medical history together with a complete head and neck examination will be conducted.

Nasal Endoscopy

Nasal endoscopy enables direct visualization of the tumor and facilitates biopsy.

Imaging studies

Imaging allows determining the size and spread of the tumor.

The following tests are usually recommended by your physician:

• CT Scan
• MRI Scan
• PET-CT Scan

Biopsy

A biopsy helps confirm that you have a plasmacytoma.

It is tested using:

• Histopathological examination
• Immunohistochemistry (IHC)
• Plasma cell markers

Further testing

As plasmacytoma can be connected to multiple myeloma, additional tests are necessary, which include:

• Complete blood count (CBC)
• Tests for kidney function
• Serum protein electrophoresis (SPEP)
• Urine protein electrophoresis (UPEP)
• Serum-free light chains test
• Bone marrow biopsy
• Whole body imaging when necessary

How is Plasmacytoma staged?

Unlike most solid tumors, plasmacytoma is mainly divided into two categories:

• Solitary extramedullary plasmacytoma
• Plasmacytoma associated with multiple myeloma

The goal of the assessment is to determine whether the disease is localized to your sinonasal cavities or has also spread to the bone marrow and other organs.

How Can Plasmacytoma Be Treated?

It depends on:

• Localized character of the disease
• Size of the tumor
• Localization of the tumor
• Association with multiple myeloma
• Health status

Treatment strategies are developed by a multidisciplinary oncology team.

Radiation Therapy

Radiation therapy is recognized as the first-line treatment for almost all localized extramedullary plasmacytomas since these tumors are very sensitive to radiation.

Surgery

It can be conducted to:

• Perform a biopsy
• Excise small localized tumors
• Alleviate nasal obstruction
• Treat some selected cases when complete excision is possible.

Surgery is usually combined with radiation therapy.

Chemotherapy

Chemotherapy is usually prescribed to:

• Patients with disease related to multiple myeloma
• Relapse
• Progression
• Patients with inadequate response to radiation therapy

Targeted Therapy and Immunotherapy

Targeted agents or immunomodulatory drugs can be administered in the presence of a multiple myeloma-related plasmacytoma, under the guidance of an oncologist-hematologist.

Can Plasmacytoma Be Cured?

Yes. There are many patients with localized Extramedullary plasmacytoma that have been well controlled or cured after radiation therapy with/without surgery.

Some of the patients might develop multiple myeloma. That is why follow-up is required.

What Is the Prognosis of Plasmacytoma?

It depends on:

• Presence of localization of the disease
• Size of the tumor
• Response to radiation therapy
• Margins after surgery (in case of surgical treatment)
• Development into multiple myeloma

Extramedullary plasmacytoma usually has a good prognosis if diagnosed and treated promptly.

What Are Possible Complications?

Without proper treatment, plasmacytoma may cause:

• Consequential growth of the tumor locally
• Consequences of the destruction of adjacent organs and structures
• Sight disturbances
• Persistent nasal obstruction
• Recurrence
• In some cases, development into multiple myeloma

Treatment-related complications depend on the methods used.

How Is the Process of Recovery After Treatments?

The recovery process depends on the type of treatment.

Patient may need:

• Timely nasal endoscopy
• CT or MRI scans
• Blood tests
• Serum protein measurement
• Frequent bone marrow examination if needed
• Rehabilitation after the extensive surgery

The vast majority of patients resume their usual activity after treatment.

Why Is Long-Term Follow-Up Necessary?

Long-term follow-up is essential even in successfully treated cases since there are patients who might experience recurrence or transformation into multiple myeloma.

Follow-up may include:

• Physical examination
• Nasal endoscopy
• Radiological examinations
• Blood and urine protein tests
• Following up with both an ENT specialist and a hematology-oncologist

Detection of recurrence or systemic disease at an early stage enables timely intervention.

Frequently Asked Questions (FAQs)

Is plasmacytoma a form of nasal cavity cancer?

Yes. Plasmacytoma is a rare cancer of plasma cell origin that can affect the nasal cavity and paranasal sinuses. It is a special form of sinonasal cancer, distinguished from other forms by its plasma cell origin.

Is plasmacytoma similar to multiple myeloma?

No. Plasmacytoma is a solitary localized cancer, while multiple myeloma is a systemic blood cancer affecting bone marrow. But there are cases when patients suffer from plasmacytoma and develop multiple myeloma later.

Is radiation therapy the principal treatment?

Yes. Radiation therapy is the basic treatment for localized extramedullary plasmacytomas due to the high sensitivity of such cancerous tumors to radiation.

Is surgery required for me?

No, not all the time. Surgery is done mostly for diagnosis, symptom relief, and excision of selected localized tumors only. Radiation is the first-line treatment for most patients.

Can there be any recurrence of plasmacytoma?

Yes, although many cases are very responsive to treatment, there is a possibility of recurrence.

Can plasmacytoma metastasize?

Localized plasmacytoma rarely spreads; however, some patients can have multiple myeloma, or it can sometimes recur.

How frequent should the follow-up be?

Most patients need follow-up at least once a year, with imaging and laboratory investigations, to detect any recurrence or systemic development of the disease.

Why choose Tender Palm Super-Speciality Hospital for Plasmacytoma Treatment in Lucknow, India?

Tender Palm Super-Speciality Hospital offers advanced Plasmacytoma treatment in Lucknow, India, at an affordable cost. We have a team of experienced hematologists and oncology specialists who provide accurate diagnosis and both non-surgical and surgical treatment options including radiation therapy, chemotherapy, and comprehensive oncological management procedures. Our Hematology and Oncology team has decades of experience in successfully treating Plasmacytoma in Lucknow, India.

To seek an Expert consultation for Plasmacytoma Treatment in Lucknow, India:

Call us at +91-9076972161
Email at care@tenderpalm.com

Request a Call Back